In a bold move aimed at fulfilling a key campaign promise, President Donald J. Trump announced his intention to sign an executive order designed to significantly reduce prescription drug and pharmaceutical prices across the United States.
The announcement, made during a press briefing at the White House, comes as part of the administration’s broader agenda to address soaring healthcare costs, a persistent issue that has burdened millions of Americans, particularly seniors and low-income families.
While specifics of the order remain under wraps, the announcement has already sparked intense debate, with supporters hailing it as a game-changer and critics questioning its feasibility and potential impact on pharmaceutical innovation.
President Trump’s announcement builds on efforts from his first term, where he prioritized lowering prescription drug costs through a series of executive actions. During the press briefing, Trump emphasized his administration’s commitment to “putting American patients first,” decrying the high prices charged by pharmaceutical companies, which he claimed have long exploited the American public.
We’re going to bring down the cost of life-saving medications so that no American has to choose between their health and putting food on the table, Trump declared, flanked by Health and Human Services Secretary Robert F. Kennedy Jr. and Commerce Secretary Howard Lutnick.
The forthcoming executive order is expected to expand on policies outlined in a previous order signed on April 15, 2025, titled “Lowering Drug Prices by Once Again Putting Americans First.”
That order directed the Department of Health and Human Services (HHS) to take steps to reduce drug prices for Medicare beneficiaries, improve transparency in the Medicare Drug Price Negotiation Program, and promote a more competitive pharmaceutical market.
According to a White House fact sheet, the April order aimed to achieve savings beyond the 22% reduction secured in the first year of the negotiation program, established under the Biden administration’s Inflation Reduction Act (IRA) of 2022.
It also sought to align Medicare payments with hospital acquisition costs, potentially lowering prices by up to 35% for certain drugs, and standardize payments across care settings, which could reduce costs by as much as 60% for treatments like cancer medications.
While the White House has not yet released the full text of the new executive order, sources familiar with the administration’s plans suggest it may include several aggressive measures.
One rumored component is the revival of a “most favored nation” pricing model, which would tie the prices Medicare pays for certain drugs to the lower amounts paid by other developed countries. This policy, initially proposed during Trump’s first term but blocked by legal challenges, has been described as a top concern for the pharmaceutical industry, with the potential to disrupt pricing models and reduce revenues.
Additionally, the order is likely to further streamline the approval process for generic drugs and biosimilars, building on Trump’s first-term efforts to increase competition in the pharmaceutical market.
The Food and Drug Administration (FDA) may be directed to expedite state programs for importing lower-cost drugs from Canada, a policy Trump championed previously. The order could also target pharmacy benefit managers (PBMs), the middlemen criticized for opaque practices that drive up drug costs, by mandating greater transparency in their fee structures.
A notable aspect of the announcement is its timing, coming just days after reports surfaced that Trump was preparing to sign such an order as early as next week. Politico, citing three sources, noted on May 8, 2025, that the administration was poised to pursue the “most favored nation” model, prompting a sharp reaction in healthcare markets.
Stocks of major pharmaceutical companies, including Eli Lilly, Merck, and AbbVie, plummeted, with declines ranging from 5.42% to 10.51%, reflecting investor concerns about the policy’s impact on industry profits.
Critics argue that the executive order could have unintended consequences. Pharmaceutical industry leaders and some Republican lawmakers have expressed concerns that aggressive price controls, such as reference pricing, could stifle innovation by reducing the funds available for research and development.
The success of Trump’s Executive Order will depend on its implementation and ability to withstand legal and political challenges. Many of the proposed measures, such as changes to the Medicare Drug Price Negotiation Program, require congressional approval, which could prove difficult given the divided nature of Congress.
Moreover, the administration’s parallel push for tariffs on pharmaceutical imports, announced earlier this month, has raised concerns about potential drug shortages and price hikes, which could counteract the Executive Order’s goals.
WHAT YOU SHOULD KNOW
As the nation awaits the formal signing of the executive order, all eyes will be on the details of its provisions and the administration’s ability to navigate a complex web of industry interests, legal constraints, and political pressures.
The White House has indicated that the executive order will be signed in the coming days, with further details to be released thereafter. Until then, the announcement serves as a powerful signal of Trump’s intent to reshape the pharmaceutical landscape, for better or for worse.
ALSO READ TOP STORIES FROM VERILY NEWS
